Category: Bio & Healthcare

Brokerage : Mirae Asset Securities Analyst : Mihwa Seo Investment Rating : Buy (Maintain) Target Price : KRW 170,000 (Maintain) Core Momentum : Value expansion driven by abundant clinical readouts across clinical-stage assets, upcoming commercialization filing, and platform PoC validation 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities & Business Outlook] 📝…

Read More “[Research] LigaChem Biosciences (141080) – Mirae Asset Securities | Clinical Milestones · Commercialization Potential · Platform PoC / 2025-05-23” »

Brokerage : Yuanta Securities Analyst : Hyunsoo Ha Investment Rating : BUY (Coverage Resumed) Target Price : KRW 150,000 (Upward) Core Momentum : Value realization driven by confirmed clinical safety of pPBD, potential of LCB39 to address toxicity hurdles, and LCB84’s differentiation in overcoming Topo1i resistance 📊 1. [Valuation & Key Financial Metrics] 🚀 2….

Read More “[Research] LigaChem Biosciences (141080) – Yuanta Securities | Payload Chemistry · Safety Profile · Differentiation / 2025-05-22” »

Brokerage : Eugene Investment & Securities Analyst : Haesun Kwon Investment Rating : BUY (Maintain) Target Price : KRW 160,000 (Maintain) Core Momentum : Sustained net profit profitability backed by rising licensing revenues alongside aggressive R&D execution and multi-pipeline clinical advancements across 2025-2026 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…

Read More “[Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17” »